TIPRANIVIR CAPSULE ON CYP450 AND P-GLYCOPROTEIN IN HEALTHY HUMANS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 替普拉那韦是一种新上市的HIV蛋白酶抑制剂，必须与利托那韦一起使用。许多药物与药物相互作用的研究表明，它具有很高的相互作用潜力。其中一些相互作用研究的结果(特别是那些与其他酶抑制剂的相互作用研究)令人惊讶，并不是基于这些相互作用的预测，而且将允许进一步探索潜在重要药物相互作用的一般信号。健康的男性和女性志愿者被选为研究人群，以消除背景抗逆转录病毒和其他疗法的混淆效应，并避免将艾滋病毒阳性患者置于单一疗法，这可能会导致对其他现有抗逆转录病毒药物的耐药性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Tipranavir is a newly-marketed HIV protease inhibitor that must be administered with ritonavir. Many individual drug-drug interaction studies have demonstrated its high interaction potential. The results of some of these interaction studies (in particular, those with other protease inhibitors) were surprising, and not predicted on the basis for these interactions, and will allow for a general signal of potentially important drug interactions for further exploration. Healthy male and female volunteers are selected for this study population to remove the confounding effects of background antiretroviral and other therapies and to avoid placing HIV positive patients on monotherapy which may lead to the development of resistance to other available antriretroviral drugs.